<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906811</url>
  </required_header>
  <id_info>
    <org_study_id>AUGCS001</org_study_id>
    <nct_id>NCT04906811</nct_id>
  </id_info>
  <brief_title>Prospective Comparison of Revolve™ and AuraGen 123 With AuraClens™ in Autologous Fat Grafting to the Breast</brief_title>
  <official_title>Prospective Comparison of the Revolve™ and AuraGen 1-2-3™ With AuraClens™ Systems in Processing of Lipoaspirate for Autologous Fat Grafting to the Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AuraGen Aesthetics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AuraGen Aesthetics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare fat graft retention over time from lipoaspirate&#xD;
      processed using two FDA-cleared devices: the Revolve System (K120902) and the AuraGen 1-2-3&#xD;
      with AuraClens Lipoaspirate Wash System (BK190433).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, prospective, randomized study enrolling patients undergoing an&#xD;
      aesthetic fat grafting procedure to the breast without a breast implant. A total of 20&#xD;
      patients will be enrolled in the study. Ten patients will receive lipoaspirate processed with&#xD;
      the Revolve and ten patients will have lipoaspirate processed with the AuraGen 1-2-3 with&#xD;
      AuraClens.&#xD;
&#xD;
      Patients will be followed on post-procedure months 3, 6, and 12. Fat graft retention will be&#xD;
      evaluated by photographic assessment by blinded reviewers, and 3D imaging. Patient&#xD;
      satisfaction will be measured using the Breast-Q - Augmentation survey.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fat volume retention at 3 months post-op</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Measurement of volume of fat graft at 3 months post-op, using 3D photography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fat volume retention at 6 months post-op</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Measurement of volume of fat graft at 6 months post-op, using 3D photography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fat volume retention at 12 months post-op</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Measurement of volume of fat graft at 6 months post-op, using 3D photography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Breast-Q - Augmentation Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Breast-Q - Augmentation Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Breast-Q - Augmentation Survey</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Autologous Fat Grafting</condition>
  <arm_group>
    <arm_group_label>Fat grafting with the AuraGen 1-2-3 with AuraClens System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the AuraGen 1-2-3 with AuraClens system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fat grafting with the Revolve System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing an aesthetic fat grafting procedure to the breast without a breast implant. Lipoaspirate processed with the Revolve System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AuraGen 1-2-3 with AuraClens system (BK190433)</intervention_name>
    <description>Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: AuraGen 1-2-3 with AuraClens system</description>
    <arm_group_label>Fat grafting with the AuraGen 1-2-3 with AuraClens System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revolve System (K120902)</intervention_name>
    <description>Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: Revolve System</description>
    <arm_group_label>Fat grafting with the Revolve System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients &gt; 18 years and &lt; 65 years of age&#xD;
&#xD;
          -  Patients undergoing an aesthetic fat grafting procedure to the breast (breast&#xD;
             augmentation) without a breast implant.&#xD;
&#xD;
          -  Patients must be able to provide written informed consent, understand and be willing&#xD;
             to comply with study-related procedures and follow-up visits.&#xD;
&#xD;
          -  Patients must be non-smokers.&#xD;
&#xD;
          -  Patients with available/adequate harvest sites for fat grafting.&#xD;
&#xD;
          -  Anticipated harvested fat volume between 400 and 1400 cc&#xD;
&#xD;
          -  Anticipated fat injection volume 150-350 cc per breast&#xD;
&#xD;
          -  Patients must agree to maintain their weight (i.e. within 5%) by not making any major&#xD;
             changes in their diet or lifestyle during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Skin rash in the treatment area.&#xD;
&#xD;
          -  Patients who smoke or use nicotine products.&#xD;
&#xD;
          -  Patients with bleeding disorders or currently taking anticoagulants.&#xD;
&#xD;
          -  Patients with a history of trauma or surgery to the treatment area.&#xD;
&#xD;
          -  Patients with a history of breast cancer.&#xD;
&#xD;
          -  Active, chronic, or recurrent infection.&#xD;
&#xD;
          -  Compromised immune system (e.g. diabetes).&#xD;
&#xD;
          -  Hypersensitivity to analgesic agents.&#xD;
&#xD;
          -  Co-morbid conditions that could limit their ability to participate in the study or to&#xD;
             comply with follow-up requirements.&#xD;
&#xD;
          -  Untreated drug and/or alcohol abuse.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Any issue that, at the discretion of the investigator, would contraindicate the&#xD;
             patient's participation.&#xD;
&#xD;
          -  Patients who do not wish to have the study area (breast) photographed&#xD;
&#xD;
        NOTE Please note that there is no remuneration for participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel A Del Vecchio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Back Bay Plastic Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yiannis Monovoukas, PhD</last_name>
    <phone>6178184008</phone>
    <email>yiannis@auragenaesthetics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Back Bay Plastic Surgery</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel A Del Vecchio, MD</last_name>
      <phone>617-262-8528</phone>
      <email>uptownbodycontouring@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Both devices are FDA-cleared. This is a marketing study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

